California State Teachers Retirement System Buys 94,609,083 Shares of Boston Scientific Corporation $BSX

Key Points

• CalSTRS dramatically increased its Boston Scientific stake by purchasing 94.6 million additional shares, bringing its ownership to 96.9 million shares, or 6.69% of the company, valued at approximately $4.14 billion.
• Institutional investors own about 89.1% of BSX, while analysts maintain a “Moderate Buy” consensus with an average price target of $71.46, despite some recent rating and target-price reductions.
• Boston Scientific exceeded quarterly earnings and revenue expectations, and its board authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares; however, more recent reports warn that a cyberattack could pressure 2026 sales and earnings.

California State Teachers Retirement System boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 4,113.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,909,037 shares of the medical equipment provider's stock after acquiring an additional 94,609,083 shares during the period. California State Teachers Retirement System owned 6.69% of Boston Scientific worth $4,136,078,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific during the 2nd quarter worth $25,000. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the fourth quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the first quarter worth about $28,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings cut shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Argus reiterated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research note on Thursday, May 28th. Finally, Jefferies Financial Group reduced their target price on Boston Scientific from $100.00 to $67.00 and set a "buy" rating on the stock in a report on Wednesday, June 24th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and an average price target of $71.46.

Boston Scientific Trading Up 0.1%

BSX opened at $45.04 on Thursday. The company's 50 day moving average is $47.08 and its 200-day moving average is $54.97. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $108.07. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market cap of $65.27 billion, a P/E ratio of 18.23, a PEG ratio of 1.04 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported progress in its RESPI clinical study, which is evaluating wearable technology for breathing monitoring. The update supports the company’s longer-term innovation pipeline, although it is not expected to materially affect near-term revenue. Boston Scientific’s RESPI Study Signals Progress in Wearable Breathing Monitoring
• Positive Sentiment: BTIG Research maintained a Buy rating while reducing its price target from $60 to $56. The revised target still implies substantial upside from recent trading levels, indicating the analyst views the cyberattack disruption as manageable over time. BTIG Research price-target update
• Neutral Sentiment: Recent commentary is examining whether investors should buy or sell BSX puts, reflecting elevated uncertainty and volatility following the earnings warning rather than a new fundamental development. BSX Stock: Is It Time To Buy Or Sell Puts?
• Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and EPS guidance. The cyberattack disrupted manufacturing and order shipments worldwide and is expected to materially affect both third-quarter and full-year results, driving the recent decline in shares. Boston Scientific says cyberattack likely to hurt 2026 sales and profit
• Negative Sentiment: Analysts also cited pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses. While product launches and cost savings may support recovery by 2028, the combination of weaker near-term demand and cybersecurity-related disruption increases execution risk. Boston Scientific’s 2026 Growth Outlook Weakens

Insiders Place Their Bets

In other news, Director David C. Habiger acquired 2,100 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.